CU22387A1 - Monoclonal anti-bodies which recognize the epidermal growth factor receptor. procedure for its preparation. - Google Patents
Monoclonal anti-bodies which recognize the epidermal growth factor receptor. procedure for its preparation.Info
- Publication number
- CU22387A1 CU22387A1 CU1992100A CU1992100A CU22387A1 CU 22387 A1 CU22387 A1 CU 22387A1 CU 1992100 A CU1992100 A CU 1992100A CU 1992100 A CU1992100 A CU 1992100A CU 22387 A1 CU22387 A1 CU 22387A1
- Authority
- CU
- Cuba
- Prior art keywords
- growth factor
- cells
- monoclonal antibodies
- antibodies
- recognize
- Prior art date
Links
- 102000001301 EGF receptor Human genes 0.000 title 1
- 108060006698 EGF receptor Proteins 0.000 title 1
- 210000004027 cell Anatomy 0.000 abstract 5
- 230000000694 effects Effects 0.000 abstract 2
- 239000003102 growth factor Substances 0.000 abstract 2
- 239000007788 liquid Substances 0.000 abstract 2
- 210000002826 placenta Anatomy 0.000 abstract 2
- 241000699670 Mus sp. Species 0.000 abstract 1
- 206010035226 Plasma cell myeloma Diseases 0.000 abstract 1
- 230000001413 cellular effect Effects 0.000 abstract 1
- 230000004927 fusion Effects 0.000 abstract 1
- 210000004408 hybridoma Anatomy 0.000 abstract 1
- 230000002401 inhibitory effect Effects 0.000 abstract 1
- 230000003211 malignant effect Effects 0.000 abstract 1
- 201000000050 myeloid neoplasm Diseases 0.000 abstract 1
- 210000002966 serum Anatomy 0.000 abstract 1
- 230000003393 splenic effect Effects 0.000 abstract 1
- 239000000725 suspension Substances 0.000 abstract 1
- 230000001225 therapeutic effect Effects 0.000 abstract 1
- 230000004614 tumor growth Effects 0.000 abstract 1
Landscapes
- Preparation Of Compounds By Using Micro-Organisms (AREA)
- Peptides Or Proteins (AREA)
Abstract
LA PRESENTE INVENCION SE RELACIONA CON LA RAMA DE LOS ANTICUERPOS MONOCLONALES Y SU UTILIZACION CON FINES DIAGNOSTICO, TERAPEUTICO E INVESTIGATIVO. ESTA INVENCION PROPORCIONA ANTICUERPOS MONOCLONALES QUE RECONOCEN EL RECEPTOR DEL FACTOR DE CRECIMIENTO EPIDERMICO (R-EGF) DE PLACENTA HUMANA, CON ALTA AFINIDAD Y CON CAPACIDAD DE INHIBIR LA UNION DEL EGF AL RECEPTOR. ESTOS ANTICUERPOS MONOCLONALES POSEEN TAMBIEN LA PROPIEDAD DE INHIBIR EL CRECIMIENTO TUMORAL EN CIERTAS LINEAS CELULARES, LA CAPACIDAD DE PRODUCIR ACTIVIDAD CELULAR CITOTOXICA DEPENDIENTE DE ANTICUERPO Y LA CAPACIDAD DE DESARROLLAR ACTIVIDAD CITOTOXICA MEDIADA POR COMPLEMENTO. LA ESENCIA DE LA INVENCION CONSISTE EN INMUNIZAR RATONES CON UNA FRACCION PARCIALMENTE PURIFICADA DEL RECEPTOR DEL FACTOR DE CRECIMIENTO EPIDERMICO DE PLACENTA HUMANA; EXTIRPAR SUS BAZOS Y PREPARAR UNA SUSPENSION DE LAS CELULAS; FUSIONAR LAS CELULAS ESPLENICAS CON CELULAS DE MIELOMA, EN PRESENCIA DE UN PROMOTOR DE FUSION; DILUIR Y CULTIVAR LAS CELU LAS; EVALUAR EL LIQUIDO SOBRENADANTE QUE CONTIENE EL HIBRIDOMA; SELECCIONAR Y CLONAR LOS HIBRIDOMAS PRODUCTORES DE ANTICUERPOS QUE REUNAN SIMULTANEAMENTE LAS CARACTERISTICAS REFERIDAS ANTERIORMENTE; RECUPERAR LOS ANTICUERPOS DEL LIQUIDO SOBRENADANTE DE LOS CLONES Y RECOGER LAS ASCITIS MALIGNAS O EL SUERO QUE CONTIENE LOS ANTICUERPOS DESEADOS.\!THE PRESENT INVENTION IS RELATED TO THE BRANCH OF MONOCLONAL ANTIBODIES AND THEIR USE FOR DIAGNOSTIC, THERAPEUTIC AND INVESTIGATIVE PURPOSES. THIS INVENTION PROVIDES MONOCLONAL ANTIBODIES THAT RECOGNIZE THE RECEPTOR OF THE EPIDERMIC GROWTH FACTOR (R-EGF) OF HUMAN PLACENTA, WITH HIGH AFFINITY AND ABILITY TO INHIBIT THE BINDING OF THE EGF TO THE RECEIVER. THESE MONOCLONAL ANTIBODIES ALSO HAVE THE PROPERTY OF INHIBITING TUMOR GROWTH IN CERTAIN CELL LINES, THE CAPACITY TO PRODUCE ANTIBODY CELLULAR ACTIVITY AND THE CAPACITY TO DEVELOP MEDOTALLY ACTIVITY. THE ESSENCE OF THE INVENTION IS TO IMMUNIZE MICE WITH A PARTIALLY PURIFIED FRACTION OF THE RECEPTOR OF THE EPIDERMIC GROWTH FACTOR OF PLACENTA HUMANA; REMOVE YOUR SPLITS AND PREPARE A SUSPENSION OF THE CELLS; MERGING SPLENIC CELLS WITH MYELOMA CELLS, IN THE PRESENCE OF A FUSION PROMOTER; DILUTE AND CULTIVATE CELLS; EVALUATE THE OVERLAPPING LIQUID CONTAINED IN THE HYBRIDOMA; SELECT AND CLONE ANTIBODY-PRODUCING HYBRIDOMES THAT SIMULTANEOUSLY COLLECT THE PREVIOUSLY REFERRED CHARACTERISTICS; TO RECOVER THE ANTIBODIES OF THE OVERLAPPING LIQUID OF THE CLONES AND TO COLLECT THE MALIGNANT ASCITIS OR THE SERUM CONTAINING THE DESIRED ANTIBODIES. \!
Priority Applications (8)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CU1992100A CU22387A1 (en) | 1992-08-18 | 1992-08-18 | Monoclonal anti-bodies which recognize the epidermal growth factor receptor. procedure for its preparation. |
| DK93202428T DK0586002T3 (en) | 1992-08-18 | 1993-08-18 | Monoclonal antibodies that recognize the epidermal growth factor receptor, its cells and methods, and preparations thereof |
| EP93202428A EP0586002B1 (en) | 1992-08-18 | 1993-08-18 | Monoclonal antibodies recognizing the epidermal growth factor receptor, cells and methods for their production and compositions containing them |
| DE69327620T DE69327620T2 (en) | 1992-08-18 | 1993-08-18 | Monoclonal antibodies to the epidermal growth factor receptor, cells and methods for their preparation and compositions containing them |
| ES93202428T ES2144440T3 (en) | 1992-08-18 | 1993-08-18 | MONOCLONAL ANTIBODIES THAT RECOGNIZE THE RECEPTOR OF THE EPIDERMIC GROWTH FACTOR, CELLS AND METHODS FOR ITS PRODUCTION AND COMPOUNDS THAT CONTAIN THEM. |
| PT93202428T PT586002E (en) | 1992-08-18 | 1993-08-18 | MONOCLONAL ANTIBODIES RECOGNIZING THE EPIDERMIC GROWTH FACTOR RECEIVER, CELLS AND METHODS FOR ITS PRODUCTION AND COMPOSITIONS THAT INCLUDE THEM |
| AT93202428T ATE188874T1 (en) | 1992-08-18 | 1993-08-18 | MONOCLONAL ANTIBODIES AGAINST THE EPIDERMAL GROWTH FACTOR RECEPTOR, CELLS AND METHODS FOR THE PRODUCTION THEREOF AND COMPOSITIONS CONTAINING THEM |
| GR20000400972T GR3033290T3 (en) | 1992-08-18 | 2000-04-20 | Arylazo chromoionophores. |
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CU1992100A CU22387A1 (en) | 1992-08-18 | 1992-08-18 | Monoclonal anti-bodies which recognize the epidermal growth factor receptor. procedure for its preparation. |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| CU22387A1 true CU22387A1 (en) | 1996-01-31 |
Family
ID=5459357
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CU1992100A CU22387A1 (en) | 1992-08-18 | 1992-08-18 | Monoclonal anti-bodies which recognize the epidermal growth factor receptor. procedure for its preparation. |
Country Status (1)
| Country | Link |
|---|---|
| CU (1) | CU22387A1 (en) |
-
1992
- 1992-08-18 CU CU1992100A patent/CU22387A1/en not_active IP Right Cessation
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| Borche et al. | Evidence that chronic lymphocytic leukemia B lymphocytes are frequently committed to production of natural autoantibodies | |
| Levy et al. | The monoclonality of human B-cell lymphomas. | |
| Koristka et al. | Engrafting human regulatory T cells with a flexible modular chimeric antigen receptor technology | |
| Schiller et al. | CD19-specific triplebody SPM-1 engages NK and γδ T cells for rapid and efficient lysis of malignant B-lymphoid cells | |
| Juhlin et al. | Monoclonal antibodies with exclusive reactivity against parathyroid cells and tubule cells of the kidney. | |
| Ellis et al. | PBDX is the XG blood group gene | |
| EP0312996B1 (en) | Anti-human bcdf monoclonal antibody | |
| US5639863A (en) | Human monoclonal antibodies specific to cell cycle independent glioma surface antigen | |
| Lutz et al. | Novel NKG2D-directed bispecific antibodies enhance antibody-mediated killing of malignant B cells by NK cells and T cells | |
| AU2016313948A1 (en) | T-cell receptor mimic (TCRm) antibodies | |
| Yamamoto et al. | Anti-idiotype monoclonal antibody carrying the internal image of ganglioside GM3 | |
| JPS62174100A (en) | Monoclonal antibody specific to gt-ii, hybridoma strain producing same and descendant thereof | |
| CU22387A1 (en) | Monoclonal anti-bodies which recognize the epidermal growth factor receptor. procedure for its preparation. | |
| Maleki et al. | Generation and characterization of anti-CD34 monoclonal antibodies that react with hematopoietic stem cells | |
| CN113493515B (en) | anti-CLDN 18A2 antibody and drug for treating tumor | |
| ES8801945A1 (en) | Monoclonal antibodies against atrial natriuretic peptides. | |
| Kim et al. | Pemphigus immunoglobulin G subclass autoantibodies: studies of reactivity with cultured human keratinocytes | |
| Aschmoneit et al. | Fc-comprising scDb-based trivalent, bispecific T-cell engagers for selective killing of HER3-expressing cancer cells independent of cytokine release | |
| JPH06213888A (en) | Immunological determination method of human 72-kda gelatinase/iv-type collagenase | |
| CN114716554A (en) | Antigen binding proteins and uses thereof | |
| Eilat et al. | Production of anti-RNA antibody by hybridoma cells: purification from mixed immunoglobulin products | |
| US7067314B2 (en) | Monoclonal antibody, its immunoreactive fragment and hybridoma | |
| ES2268961B1 (en) | NEW EPCR SOLUBLE PROTEIN OF NON-PROTEOLITICAL ORIGIN AND ITS USE. | |
| Mandal et al. | Cancer-oocyte SAS1B protein is expressed at the cell surface of multiple solid tumors and targeted with antibody-drug conjugates | |
| Shin et al. | Characterization of monoclonal antibodies against human leukocyte common antigen (CD45) |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| MK | Ceased due to expiration of term |